

Summary of risk management plan for Clindamycin 150 mg/ml Solution for injection/infusion (clindamycin)

This is a summary of the risk management plan (RMP) for Clindamycin 150 mg/ml Solution for injection/infusion (hereinafter referred to as CLINDAMYCIN). The RMP details important risks of CLINDAMYCIN, how these risks can be minimised, and how more information will be obtained about CLINDAMYCIN's risks and uncertainties (missing information).

CLINDAMYCIN's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how CLINDAMYCIN should be used.

Important new concerns or changes to the current ones will be included in updates of CLINDAMYCIN's RMP.

I. The medicine and what it is used for

CLINDAMYCIN is authorised for the treatment of the following severe infections caused by clindamycin susceptible microorganisms in adults, adolescents and children ≥ 1 months:

- Bone and joint infections
- Chronic sinusitis
- Infections of the lower respiratory tract
- Intra-abdominal infections
- Pelvic and female genital infections
- Skin and soft tissue infections
- Dental infection
- Treatment of bacteraemia that occurs in association with, or is suspected to be associated with any of the infections listed above and
- Treatment of opportunistic infections from *Toxoplasma gondii* and *Pneumocystis jirovecii* in adult immunocompromised patients

In case of aerobic infections clindamycin constitutes an alternative treatment in case other antibacterial agents are inactive or contraindicated (e.g. in case of allergy to penicillins). In case of anaerobic infections a treatment with clindamycin as first choice agent can be envisaged. In case of polymicrobial infection, consideration should be given to use in combination with an agent with adequate activity against Gram-negative bacteria (see SmPC for the full indication).

It contains clindamycin as the active substance and it is given by intramuscular injection or intravenous infusion.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of CLINDAMYCIN, together with measures to minimise such risks and the proposed studies for learning more about CLINDAMYCIN's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of CLINDAMYCIN are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of CLINDAMYCIN. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the longterm use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of CLINDAMYCIN.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for CLINDAMYCIN.